National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies
N/A
N/A
N/A
N/A
N/A
Open (Enrolling by invite only)
Both
Rheumatoid Arthritis
Both
Rheumatoid Arthritis
Trial Information
National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies
Inclusion Criteria:
- RA and started treatment with certolizumab pegol (Cimzia®; CZP) or non-biologic DMARD
within the last 6 months
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Number of participants with lymphoma
Outcome Description:
Number of participants with lymphoma during the observational period (up to 6 years)
Outcome Time Frame:
6 years
Safety Issue:
Yes
Principal Investigator
Frederick Wolfe, M.D.
Investigator Role:
Study Director
Investigator Affiliation:
National Data Bank for Rheumatic Disease
Authority:
United States: Institutional Review Board
Study ID:
RA0005
NCT ID:
NCT01095393
Start Date:
September 2009
Completion Date:
February 2016
Related Keywords:
- Rheumatoid Arthritis
- Certolizumab Pegol
- CZP
- Cimzia®
- NDB
- registry
- Arthritis
- Arthritis, Rheumatoid
- Rheumatic Diseases
Name | Location |
|---|
